Skip to content
Study details
Enrolling now

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

Brigham and Women's Hospital
NCT IDNCT05553782ClinicalTrials.gov data as of Apr 2026
Phase

EARLY_PHASE1

Target enrollment

30

Study length

about 8.3 years

Ages

18+

Locations

2 sites in MA

What this study is about

This trial is testing a new device, called an implantable microdevice (IMD), as a possible treatment for salivary gland cancers and head and neck cancers. The goal of this early-phase trial is to evaluate the safety and effectiveness of the IMD in adults.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Use Implantable Microdevice (IMD)

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Grade 3 or Higher Treatment-Related Toxicity Rate

Secondary: Biomarker levels, Gene Expression Level, Pharmacodynamic (PD), Tumor Response

Body systems

Oncology